Add Yahoo as a preferred source to see more of our stories on Google. No doubt about it: Statins lower artery-clogging cholesterol and cut risks of cardiovascular disease, heart attacks and strokes.

Statin use among patients with chronic liver disease was associated with a reduced risk of liver cancer and hepatic decompensation. Users had a 33% lower risk for liver cancer and a 22% lower risk for ...

Please provide your email address to receive an email when new articles are posted on . Patients who used statins had a reduced risk for HCC, hepatic decompensation and fibrosis progression.

Millions of Americans take statins daily to manage their cholesterol levels and reduce heart disease risk. These medications have long been considered workhorses in cardiovascular care, but new ...

Long-term use of statins may delay or deflect the development of hepatocellular carcinoma in adults with chronic liver disease, as well as in the general population, emerging research, including ...

Statins, originally developed to lower circulating cholesterol by inhibiting HMG-CoA reductase, have emerged as multifaceted agents in the management of chronic liver disorders. Beyond lipid reduction ...

The analysis included 16,501 participants: 3610 statin users and 12,891 nonusers. HealthDay News — For patients with chronic liver disease, statin use is associated with a reduced risk for ...

If your doctor has mentioned fatty liver disease after a recent round of blood tests, take a deep breath—you're in good ...

If it continues to work in further studies, a gene therapy in development could eliminate the need for daily pills or regular ...

As we reach a certain age, many of us begin reaching for our pill bottles, as well as a nice glass of red. With more than 10 million people in England now eligible for statins, the cholesterol ...

No doubt about it: Statins lower artery-clogging cholesterol and cut risks of cardiovascular disease, heart attacks and strokes. But are the drugs helpful if you have fatty liver disease, or can they ...